Commencement Of Phase II Clinical Study Of GDC-0084
- Written by LATEST ASIANET NEWS RELEASES
- Category: Asia Net
SYDNEY, March 28, 2018 /PRNewswire-AsiaNet/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology drug development company, is pleased to announce commencement of an international phase II clinical trial of its lead program, GDC-0084. Key Points- First site, St......




